Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Business Wire • Feb 20, 2026

Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.

Zacks Investment Research • Feb 19, 2026

Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Feb 19, 2026

CSLLY vs. EXAS: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Feb 16, 2026

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Seeking Alpha • Feb 15, 2026

Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for the fourth quarter of 2025 and $3.25 billion for the full year of 2025, both ended December 31, 2025. “In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests.

Business Wire • Feb 13, 2026

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago.

Zacks Investment Research • Feb 13, 2026

Baron Opportunity Fund Q4 2025 Portfolio Activity

We invest in secular growth and innovative businesses across all market capitalizations, with the bulk of the portfolio landing in the large-cap zone. We recently initiated a position in Axon Enterprise. We exited our successful investment in Exact Sciences Corporation after Abbott Laboratories announced it was acquiring the company for approximately $23 billion in cash.

Seeking Alpha • Feb 12, 2026

Alger Mid Cap 40 ETF Q4 2025 Portfolio Update

The Alger Mid Cap 40 ETF underperformed the Russell Midcap Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Micron Technology, Inc. and MongoDB, Inc. were among the top contributors to performance. Roblox Corp., Nebius Group, and Robinhood Markets, Inc. were among the top detractors from performance.

Seeking Alpha • Feb 12, 2026

Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences' U.S. Patent No. 11,970,746 (the '746 patent) unpatentable. This decision follows the PTAB's July 2025 Final Written.

Business Wire • Feb 6, 2026